A phase I dose-escalating study of intratumoral LTX-315 treatment tested in patients with advanced solid tumors showed that LTX-315 was safe with activities including shrinking the tumors, inducing CD8+ T-cell infiltration into the tumor microenvironment and expanding tumor-associated T-cell clones [23]. The gene discussed is CD8A; the disease is neoplasm.